Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment
How did autism care become a big business? Can gene therapy be profitable? And whatever happened to that $40 billion merger?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Tara Bannow joins us to discuss how private equity’s mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of Bluebird Bio’s long-awaited FDA approval, a controversial treatment for ALS, and the ups and downs of Merck’s reported interest in buying Seagen.
